Avalyn Pharma Inc. Common Stock (AVLN)
Stock · NASDAQ · Health Care
$23.66as of 10/16/2026
Price chart
Active signals
No technical signal is currently active for this symbol.
Resistance level
$27.91
Industry
Biotechnology: Pharmaceutical Preparations
About AVLN
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfeni…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 55
- Website
- www.avalynpharma.com
Fundamentals
- 1-day range
- $24.71$25.91
- Market cap
- $1.45B
- P/E (trailing)
- —
- P/E (forward)
- -13.05
- EPS (trailing)
- $-2.26
- Dividend yield
- —
- Beta
- 1.28
- Avg. volume
- 242.0K
52-week range
$23.08$40.17
Next earnings: November 16, 2026 · EPS estimate $-0.79
Forecasts
5 analyst ratings
Buy 90%
Hold 10%
Sell 0%
1-year price forecast
High
$80
+238.1%
Median
$60
+153.6%
Low
$52
+119.8%
Avalyn Pharma Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- AVLNAvalyn Pharma Inc. Common Stock$23.66▼ 3.98%Market cap $1.45BP/E —$23.08$40.17
- AVBPArriVent BioPharma Inc. Common Stock$16.66▼ 0.77%Market cap $1.44BP/E —$11.36$35.83
- PAHCPhibro Animal Health Corporation Class A Common Stock$38.82▲ 2.21%Market cap $1.44BP/E 15.44$28.25$60.08
- XNCRXencor Inc. Common Stock$22.85▼ 4.79%Market cap $1.48BP/E —$10.38$30.61
- HROWHarrow Inc. Common Stock$27.28▼ 5.11%Market cap $1.49BP/E —$26.96$54.85
- LBRXLB Pharmaceuticals Inc Common Stock$36.74▲ 0.14%Market cap $1.38BP/E —$14.32$50.16
- INVAInnoviva Inc. Common Stock$20.78▼ 0.38%Market cap $1.56BP/E 4.25$16.52$25.15
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AVLN Avalyn Pharma Inc. Common Stock | $1.45B | — | $23.66 | ▼ 3.98% | $23.08$40.17 |
| AVBP ArriVent BioPharma Inc. Common Stock | $1.44B | — | $16.66 | ▼ 0.77% | $11.36$35.83 |
| PAHC Phibro Animal Health Corporation Class A Common Stock | $1.44B | 15.44 | $38.82 | ▲ 2.21% | $28.25$60.08 |
| XNCR Xencor Inc. Common Stock | $1.48B | — | $22.85 | ▼ 4.79% | $10.38$30.61 |
| HROW Harrow Inc. Common Stock | $1.49B | — | $27.28 | ▼ 5.11% | $26.96$54.85 |
| LBRX LB Pharmaceuticals Inc Common Stock | $1.38B | — | $36.74 | ▲ 0.14% | $14.32$50.16 |
| INVA Innoviva Inc. Common Stock | $1.56B | 4.25 | $20.78 | ▼ 0.38% | $16.52$25.15 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For FridayBenzinga · 10/2/2026
- Raymond James Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $60Benzinga · 10/2/2026
- Avalyn Pharma (AVLN) Following AP02 Phase 1 Data Is Its Valuation Too PriceyYahoo · 9/23/2026
- Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety ProfileYahoo · 9/21/2026
- Avalyn Pharma Says Respiratory Research Publishes Detailed Results From Two Phase 1 Clinical Trials Of AP02 In Healthy Volunteers And Patients With IPF, Validating Inhaled Antifibrotic ApproachBenzinga · 9/21/2026
- Avalyn Appoints Robert J. Meyer, MD, to its Board of DirectorsYahoo · 9/16/2026
- Avalyn Pharma Inc. (AVLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/14/2026
Insider Activity
Insider Actions →Acquired
6.55M
Disposed
73.45M
- Meyer Robert J. · September 15, 2026 · Grant31.2K
- George Simeon · May 1, 2026 · Conversion354.8K
- FMR LLC · May 1, 2026 · Conversion377.9K
- FMR LLC · May 1, 2026 · Conversion225.8K
- FMR LLC · May 1, 2026 · Conversion872.9K
- FMR LLC · May 1, 2026 · Conversion80.3K
- FMR LLC · May 1, 2026 · Conversion727.6K
- Novo Holdings A/S · May 1, 2026 · Conversion12.56M
- Novo Holdings A/S · May 1, 2026 · Conversion5.59M
- Novo Holdings A/S · May 1, 2026 · Conversion25.90M
- Novo Holdings A/S · May 1, 2026 · Conversion1.99M
- Novo Holdings A/S · May 1, 2026 · Conversion18.00M
- Novo Holdings A/S · May 1, 2026 · Buy555.6K @ $18
- Novo Holdings A/S · May 1, 2026 · Conversion3.33M
- Jill Carroll · May 1, 2026 · Conversion9.42M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
AVLN releases Phase 1 data for AP02 inhaled therapy
Avalyn Pharma released Phase 1 results for its inhaled antifibrotic candidate AP02. The trials in healthy volunteers and patients with idiopathic pulmonary fibrosis showed lung‑targeted delivery and an encouraging safety profile. The publication follows recent discussion of the company's valuation and adds clinical evidence supporting the inhaled approach.
AVLN releases Phase 1 data for AP02 inhaled therapy. Avalyn Pharma released Phase 1 results for its inhaled antifibrotic candidate AP02. The trials in healthy volunteers and patients with idiopathic pulmonary fibrosis showed lung‑targeted delivery and an encouraging safety profile. The publication follows recent discussion of the company's valuation and adds clinical evidence supporting the inhaled approach.